Videos

Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.

The Mayo Clinic expert highlights exciting advancements being made in chimeric antigen receptor T-cell therapy for blood cancer.

The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

The MD Anderson Cancer Center expert discussed how researchers are using genetic alterations to drive specific therapies at the 16th International Congress of the Society for Melanoma Research.

The Memorial Sloan Kettering Cancer Center expert discussed a study he designed to discover why and how melanoma metastasizes, at the 16th International Congress of the Society for Melanoma Research.

Fergus Couch, PhD, from the Mayo Clinic, discusses with CancerNetwork about the new research with the CARRIERS study for African American patients with breast cancer.

Marjorie Zauderer, MD, from Memorial Sloan Kettering Cancer Center, discussed new immunotherapy approaches at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

CancerNetwork® spoke with Dr. Sara Hurvitz, associate professor of medicine at the University of California, Los Angeles, about therapy options for breast cancer. 

CancerNetwork® spoke with Dr. William Wood on the clinical risk of chemotherapy in early breast cancer. 

Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.

Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study.

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.

Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ.

Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma.

Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma.

Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.

Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.

Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.

Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.

Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019.

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers.

Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.